Methods and compositions for treatment of cancer using oncolytic rsv activity
AssigneeBoard of Regents, The University of Texas System
InventorsSantanu Bose, Bandana Chatterjee
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
Claims67
A method of treating a neoplasm in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby treating the neoplasm in the subject.
A method of treating a cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby treating the cancer in the subject.
A method of reducing metastasis of a primary cancer in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing metastasis of a primary cancer in the subject.
A method of reducing tumor size and/or tumor burden in a subject comprising a tumor, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing tumor size and/or tumor burden in the subject.
A method of inducing apoptosis of a neoplastic or tumor cell in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby inducing apoptosis of a neoplastic or tumor cell in the subject.
A method of reducing pain caused by a tumor in a subject, comprising administering to the subject an oncolytically effective amount of a respiratory syncytial virus (RSV), thereby reducing pain caused by the tumor in the subject.
A method of delivering a respiratory syncytial virus (RSV) to a tumor cell in a subject, comprising administering to the subject a recombinant respiratory syncytial virus (RSV) comprising a protein that specifically binds a tumor antigen on the tumor cell.
A method of increasing the sensitivity of a tumor cell to radiation, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), thereby increasing the sensitivity of the tumor cell to radiation.
A method of increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), thereby increasing the sensitivity of the tumor cell to a chemotherapeutic agent.
A method of sensitizing a tumor cell to an immune response against RSV, comprising infecting the tumor cell with a respiratory syncytial virus (RSV), whereby the respiratory syncytial virus expresses respiratory syncytial virus antigen on the surface of the tumor cell, thereby sensitizing the tumor cell to an immune response against respiratory syncytial virus.
A method of treating a tumor or neoplasm in a subject, comprising removing the tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), thereby treating a tumor or neoplasm in the subject.
A method of reducing the likelihood of recurrence of a tumor or neoplasm in a subject, comprising removing the tumor or neoplasm from the subject and administering to the subject an oncolytic amount of a respiratory syncytial virus (RSV), thereby reducing the likelihood of recurrence of a tumor or neoplasm in the subject.
A method of eliminating or reducing the number of neoplastic cells in an ex vivo population of neoplastic cells and normal cells, comprising contacting the population with a respiratory syncytial virus (RSV) under conditions whereby the respiratory syncytial virus can infect the cells and kill the neoplastic cells, thereby eliminating or reducing the number of neoplastic cells in the ex vivo population.
A method of preparing a cellular composition or organ for transplantation into a subject, comprising contacting the cellular composition or organ with a respiratory syncytial virus (RSV) under conditions whereby the respiratory syncytial virus can infect the cells of the cellular composition and/or organ and kill neoplastic cells present in the cellular composition or organ, thereby preparing the cellular composition or organ for transplantation into the subject.
A composition comprising a respiratory syncytial virus and one or more oncolytic virus selected from the group consisting of either nonengineered or engineered adenovirus, reovirus (e.g., Reolysin®), herpesvirus, Newcastle disease virus, vaccinia virus, measles virus, Coxsackie virus, vesicular stomatitis virus, parvovirus, influenza virus and any combination thereof.
A method of treating a cancer in a subject, comprising delivering a heterologous nucleotide sequence encoding an oncolytic respiratory syncytial virus protein to a tumor cell in the subject under conditions whereby the oncolytic RSV protein is produced in the tumor cell, resulting in killing of the tumor cell, thereby treating the cancer in the subject.
A complex comprising:
- a) an RSV particle, wherein the RSV particle comprises a viral genome lacking a functional RSV gene;
- and
- b) a nanoparticle comprising nucleic acid comprising the functional RSV gene under the control of a cell-specific promoter.
A nanoparticle comprising a nucleic acid encoding a viral protein under the direction of a cell-specific promoter.
Dependencies are inferred from the claim text.